///// VISIOPHARM®



Stay confident in your biomarker scoring – every time

Manual biomarker scoring can be both time-consuming and inconsistent challenges that become even more critical with classifications like HER2-low and -ultralow. The Insight platform enables AI-driven, fully automated image analysis APPs to provide precise, reliable biomarker scoring. With Insight, you can eliminate variability and focus on what truly matters: making confident, informed decisions.

The Insight Advantages

- **Improved consistency** Standardized quantification ensures reproducibility across samples and pathologists.
- **Faster results** Al-powered, high-throughput automation streamlines workflows and reduces turnaround time.
- Focus on decisions, not manual work Minimize time spent on manual assessment and more on making informed decisions.
- **Confidence in every call** Accurate biomarker assessments aligned with guidelines for clear, precise results.
- Seamless integration Works with major PACS/IMS/ LIS systems, including Proscia, Sectra, PathAI, Fujifilm, INFINITT, Corista, Paige, Philips, and more.



Insight results displayed in the Sectra IDS7.



Lab workflow, PACS upload


Assessment



Your review


Decision

Our fully automated, AI-based image analysis provides precise quantifications to assess biomarker expressions for evaluation in various cancer indications.




HER2, breast cancer


Fully automated single-cell approach for HER2 Score assessment, bringing confidence to scoring also low expression cases.




Ki-67, breast cancer Quantifies cell proliferation in invasive tissue, returning a proliferation index for the entire tumor region.



ER & PR, breast cancer These two APPs measure ER and PR positivity and provide the percentage of positive cells, the total cell number as well as an Allred score.




PD-L1, lung cancer (NSCLC) Evaluates whole tumor sections and returns a Tumor Proportion Score (TPS), ensuring objective PD-L1 expression analysis.



Lymph node metastasis, breast & colon cancer

Identifies even small and hard-to-spot metastases in lymph nodes (H&E), enhancing sensitivity and reducing the need for additional IHC staining.



Prostate cancer, detection and grading, H&E (IVDD)

Detects invasive tumor areas in needle core biopsies and provides automated Gleason scoring, ensuring objective and reproducible grading.





Ready to bring confidence and reproducibility to your biomarker assessment?

Stay confident



Contact us





16978-05-2025